Rifabutin + Rifabutin + Atazanavir + Ritonavir
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antivirals/HIV
Conditions
Antivirals/HIV
Trial Timeline
Apr 1, 2008 → Aug 1, 2008
NCT ID
NCT00646776About Rifabutin + Rifabutin + Atazanavir + Ritonavir
Rifabutin + Rifabutin + Atazanavir + Ritonavir is a phase 1 stage product being developed by Bristol Myers Squibb for Antivirals/HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00646776. Target conditions include Antivirals/HIV.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00646776 | Phase 1 | Completed |